RGLS Shares Outstanding History



Below is a table of the RGLS shares outstanding history going back to 10/3/2012:

Date RGLS Shares Outstanding
10/3/2012181156
11/16/2012298575
2/14/2013299026
5/10/2013300061
8/12/2013301298
11/8/2013348144
2/7/2014359734
4/25/2014361307
7/25/2014361603
11/3/2014405032
2/6/2015420973
4/23/2015425145
7/24/2015432663
10/30/2015436189
2/19/2016439206
4/27/2016439842
7/29/2016440169
10/28/2016441028
2/24/2017441103
4/28/2017443186
7/28/2017864881
11/3/2017866293
2/23/2018866326
5/4/2018869330
8/3/2018873313
10/4/2018873313
11/2/2018875034
3/8/20191.07M
5/7/20192.05M
8/2/20192.08M
9/28/2012276256
11/8/20192.09M
3/6/20202.10M
5/8/20202.76M
8/7/20203.59M
10/30/20203.92M
3/5/20217.25M
5/7/20217.49M
8/6/20218.70M
11/5/20218.70M
3/4/202214.60M
5/6/202214.60M
11/4/202216.84M
3/17/202316.84M
5/5/202319.48M
8/4/202319.48M
11/3/202320.22M
3/15/202465.47M
5/3/202465.47M
8/2/202465.47M

Also see: RGLS Market Cap History
RGLS YTD Return
RGLS Historical Shares Outstanding:
+64.47% CAGR
RGLS Historical Shares Outstanding: +64.47% CAGR

Mouse over chart for data details
10/3/2012 ...8/2/2024
Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program. We show 50 historical shares outstanding datapoints in our coverage of RGLS's shares outstanding history.

Understanding the changing numbers of RGLS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like RGLS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching RGLS by allowing them to research RGLS shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree RGLS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Regulus Therapeutics (RGLS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

RGNX Shares Outstanding History
RIGL Shares Outstanding History
RLAY Shares Outstanding History
RLMD Shares Outstanding History
RLYB Shares Outstanding History
RMD Shares Outstanding History
RMED Shares Outstanding History
RMTI Shares Outstanding History
RNA Shares Outstanding History
RNAC Shares Outstanding History
More Healthcare companies »

 

RGLS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.